Physician profile
Ruben Mechell
NPI 1467772863
$6,190.08
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $2,159 · 2021: $1,055 · 2022: $1,335 · 2023: $68.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,484.71 | 2019-2023 | Prophecy |
| Medinc of Texas | $854.00 | 2020 | |
| Arthrex, INC. | $802.45 | 2020-2022 | |
| Smith+Nephew, INC. | $517.73 | 2019-2022 | |
| Horizon Therapeutics Plc | $363.10 | 2019-2022 | |
| Sandoz INC. | $165.75 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $108.83 | 2020-2022 | |
| Bioventus LLC | $75.00 | 2019-2022 | |
| Treace Medical Concepts, INC. | $74.45 | 2022-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.45 | 2020-2022 | |
| Kerecis Limited | $60.87 | 2020-2021 | |
| Kci USA, INC. | $58.57 | 2019-2020 | |
| Abbvie INC. | $58.40 | 2022 | |
| Triad Life Sciences INC. | $56.19 | 2022 | |
| Organogenesis INC. | $52.47 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $45.58 | 2022 | |
| Medtronic, INC. | $43.50 | 2022 | |
| Zyla Life Sciences, INC. | $40.12 | 2019 | |
| Merck Sharp & Dohme LLC | $37.32 | 2019 | |
| Baudax Bio INC. | $36.03 | 2021-2022 | |
| Fidia Pharma USA INC. | $35.70 | 2020-2021 | |
| Heron Therapeutics, INC. | $32.12 | 2021 | |
| Acera Surgical, INC. | $29.52 | 2022 | |
| Sebela Pharmaceuticals INC. | $19.50 | 2019 | |
| Melinta Therapeutics, LLC | $18.40 | 2021 | |
| Medline Industries Lp | $15.85 | 2022 | |
| Journey Medical Corporation | $15.02 | 2021 | |
| Assertio Therapeutics, INC. | $12.94 | 2020 | |
| Nabriva Therapeutics, Plc | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Mechell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.